Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaroAcT: Darolutamide vs Enzalutamide in CRPC
NCT04157088Phase 2Terminated
- Sponsor
- Bayer
- Start
- Dec 2019
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Bayer. Primary endpoint: Number of Participants With a Worsening in TUG Time During the 24-Week Period. Started Dec 2019; status: terminated.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04157088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157088.